Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299–5p regulated de novo expression of osteopontin
暂无分享,去创建一个
Yaguang Xi | Jingfang Ju | Y. Xi | J. Ju | R. Samant | Brandon J. Metge | L. Shevde | A. Mitra | J. King | Lalita A Shevde | Brandon J Metge | Aparna Mitra | Judy A King | Rajeev S Samant | Rajeev S. Samant
[1] J. Winstanley,et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. , 2002, Cancer research.
[2] V. Castronovo,et al. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.
[3] R Folberg,et al. Vasculogenic mimicry and tumor angiogenesis. , 2000, The American journal of pathology.
[4] F. O'Malley,et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] James P. Freyer,et al. The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model , 2004, Journal of biomolecular screening.
[6] A. Chambers,et al. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation , 2006, Clinical & Experimental Metastasis.
[7] Olga Kovalchuk,et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.
[8] J. Lee,et al. Expression of osteopontin and osteonectin in breast cancer. , 1998, Journal of Korean medical science.
[9] K. Laderoute,et al. Enhancement of transforming growth factor-a . synthesis in multicellular tumour spheroids of A 431 squamous carcinoma cells , 2022 .
[10] G. Kundu,et al. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. , 2006, Cancer research.
[11] Miao Sun,et al. MicroRNA and cancer: Current status and prospective , 2006, International journal of cancer.
[12] Chang-Zheng Chen,et al. MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.
[13] A. Alessandrini,et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. , 2002, Experimental cell research.
[14] G. Kundu,et al. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. , 2008, Cancer research.
[15] R. Sutherland. Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.
[16] B. Desoize,et al. Cell culture as spheroids: an approach to multicellular resistance. , 1998, Anticancer research.
[17] Catherine Charbonnel,et al. Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen , 2008, Breast Cancer Research and Treatment.
[18] V. Bramwell,et al. The functional and clinical roles of osteopontin in cancer and metastasis. , 2001, Current molecular medicine.
[19] L. Rodrigues,et al. The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.
[20] G. Dontu,et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.
[21] K. Hruska,et al. The Integrin {alpha}v{beta}3 and CD44 Regulate the Actions of Osteopontin on Osteoclast Motility , 2003, Calcified Tissue International.
[22] Y. Yatabe,et al. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.
[23] Michael J Kerin,et al. MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management , 2008, Clinical Cancer Research.
[24] Barbara McGrogan,et al. Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.
[25] V. Ambros. microRNAs Tiny Regulators with Great Potential , 2001, Cell.
[26] Fred R. Miller,et al. Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.
[27] J. Brugge,et al. Use of Three-Dimensional Basement Membrane Cultures to Model Oncogene-Induced Changes in Mammary Epithelial Morphogenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.
[28] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[29] R. Kerbel,et al. TGF-β gene expression depends on tissue architecture , 1993, In Vitro Cellular & Developmental Biology - Animal.
[30] W. Cho. OncomiRs: the discovery and progress of microRNAs in cancers , 2007, Molecular Cancer.
[31] M. Okazaki,et al. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. , 2004, Dental materials journal.
[32] R. Samant,et al. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. , 2008, Biochimica et biophysica acta.
[33] Chris Jay,et al. miRNA profiling for diagnosis and prognosis of human cancer. , 2007, DNA and cell biology.
[34] G. Kundu,et al. Osteopontin Induces Nuclear Factor κB-mediated Promatrix Metalloproteinase-2 Activation through IκBα/IKK Signaling Pathways, and Curcumin (Diferulolylmethane) Down-regulates These Pathways* , 2003, The Journal of Biological Chemistry.
[35] G. Kundu,et al. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. , 2003, The Journal of biological chemistry.
[36] D. Medina,et al. Re-evaluation of mammary stem cell biology based on in vivo transplantation , 2008, Breast Cancer Research.
[37] Susan G Hilsenbeck,et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.
[38] V. Bramwell,et al. Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.
[39] D. Denhardt,et al. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors * , 2002, Journal of cellular biochemistry.
[40] C. Ries,et al. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab , 2009, Oncogene.
[41] B. Teicher,et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[42] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[43] A. Sundan,et al. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. , 2004, Experimental oncology.
[44] J. Rak. Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis? , 2006, Medical hypotheses.
[45] A. Chambers,et al. The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies , 2001, Journal of Mammary Gland Biology and Neoplasia.
[46] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[47] G. Kundu,et al. The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C α/c-Src/IκB Kinase α/β–Dependent Prostate Tumor Progression and Angiogenesis , 2006 .
[48] K. Nishio,et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. , 2003, Cancer letters.
[49] G. Weiss,et al. MicroRNAs and cancer: past, present, and potential future , 2008, Molecular Cancer Therapeutics.
[50] N. Fedarko,et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] Weiyun Zhu,et al. Impact of tiny miRNAs on cancers. , 2007, World journal of gastroenterology.
[52] J. F. Harris,et al. Osteopontin expression in a group of lymph node negative breast cancer patients , 1998, International journal of cancer.
[53] M. Hendrix,et al. Molecular biology of breast cancer metastasis Molecular expression of vascular markers by aggressive breast cancer cells , 2000, Breast Cancer Research.
[54] Y. Pekarsky,et al. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. , 2007, Best practice & research. Clinical haematology.
[55] M. Daidone,et al. Breast cancer stem cells: an overview. , 2006, European journal of cancer.
[56] R. Wechsler-Reya,et al. Hit 'em where they live: targeting the cancer stem cell niche. , 2007, Cancer cell.
[57] Kornelia Polyak,et al. Breast cancer: origins and evolution. , 2007, The Journal of clinical investigation.
[58] S. Philip,et al. Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-κB-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells* , 2001, The Journal of Biological Chemistry.
[59] K. Polyak. Is Breast Tumor Progression Really Linear? , 2008, Clinical Cancer Research.
[60] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[61] A. Waage,et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. , 2004, Haematologica.
[62] J. F. Harris,et al. Osteopontin expression in lung cancer. , 1996, Lung cancer.
[63] G. Weber,et al. An osteopontin splice variant induces anchorage independence in human breast cancer cells , 2006, Oncogene.
[64] R. Kerbel,et al. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. , 1994, Cold Spring Harbor symposia on quantitative biology.
[65] Tyler E. Miller,et al. MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.
[66] R. Kerbel,et al. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. , 2001, Gastroenterology.
[67] G. Casey,et al. Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435 , 2006, Clinical & Experimental Metastasis.
[68] Massimo Negrini,et al. Breast cancer metastasis: a microRNA story , 2008, Breast Cancer Research.
[69] V. Ambros,et al. The regulation of genes and genomes by small RNAs , 2007, Development.
[70] A. Ivascu,et al. Diversity of cell-mediated adhesions in breast cancer spheroids. , 2007, International journal of oncology.
[71] M. O'hare,et al. Three-dimensional in vitro tissue culture models of breast cancer — a review , 2004, Breast Cancer Research and Treatment.
[72] Lin Zhang,et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis , 2008, Nature Cell Biology.
[73] Domenico Coppola,et al. MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.
[74] Mansoor M Ahmed,et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. , 2006, Current molecular medicine.
[75] M. Clarke,et al. Self-renewal and solid tumor stem cells , 2004, Oncogene.
[76] F. Miller,et al. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. , 2000, Journal of the National Cancer Institute.
[77] Linheng Li,et al. Normal stem cells and cancer stem cells: the niche matters. , 2006, Cancer research.
[78] W. Gerald,et al. Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.
[79] F. Miller,et al. Progression of Premalignant MCF10AT Generates Heterogeneous Malignant Variants with Characteristic Histologic Types and Immunohistochemical Markers , 2000, Breast Cancer Research and Treatment.
[80] S. North,et al. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. , 2005, Cancer letters.
[81] R. Weinberg,et al. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.